Name: Pearce IP
Address: Level 5/20 Bond St, Sydney, NSW, 2000, AU
Telephone: (02) 9023 9988
Price range: $$

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

Pearce IP BioBlast®: w/e 08 October 2021

By Naomi Pearce | Oct 11, 2021

Read more

27 Sep 21 | CA | Apobiologix announced that Health Canada has approved Bambevi® (biosimilar bevacizumab) in combination with chemotherapy to treat specific types of colorectal, lung...
Pearce IP honours UN International Day of the Girl Child by helping to end slavery

By Pearce IP | Oct 11, 2021

Read more

October 11 is UN International Day of the Girl Child, a day where we together recognise the unique challenges girls face around the world and seek to advance the rights of girls and...
Australian pharmacists raise concerns over proforma letters provided by AbbVie

By Bioblast Editor | Oct 09, 2021

Read more

The Australian reported that Australian pharmacists have raised concerns over proforma letters provided by AbbVie to prescribing doctors (specialist rheumatologists and gastroenterologists) and public hospital clinics instructing chemists to only dispense Humira® branded ad...
Aggregate savings enabled by biosimilars 4.3 times higher than that of generics

By Bioblast Editor | Oct 08, 2021

Read more

A new study published in Stat News reported that the aggregate savings enabled by biosimilars in the US was 4.3 times higher than that of generics.
Janssen submits sBLA for Stelara® (ustekinumab

By Bioblast Editor | Oct 08, 2021

Read more

Janssen announced the submission of a sBLA to the FDA seeking expanded approval of Stelara® (ustekinumab) to treat paediatric patients aged 5 years and older with juvenile psoriatic arthritis.
AU's TGA approves Enhertu® (trastuzumab deruxtecan)

By Bioblast Editor | Oct 08, 2021

Read more

Australia’s TGA approved AstraZeneca’s Enhertu® (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens.
US District Court dismisses Humira® trade secrets lawsuit brought by AbbVie against Alvotech

By Bioblast Editor | Oct 08, 2021

Read more

The US District Court for the Northern District of Illinois dismissed the Humira® trade secrets lawsuit brought by AbbVie against Alvotech for lack of jurisdiction.
Xbrane Biopharma and AGC Biologics enter into agreement for Xcimzane™ (certolizumab pegol)

By Bioblast Editor | Oct 07, 2021

Read more

Xbrane Biopharma and AGC Biologics entered into an agreement to manufacture Xcimzane™ (certolizumab pegol) for clinical development.
MSD and Pfizer pneumococcal conjugate vaccine settlement prolongs uncertainty regarding Australian product claims

By Naomi Pearce | Oct 06, 2021

Read more

Recently, Merck Sharp & Dohme (MSD) (known as Merck & Co., Inc. in the US and Canada) announced a settlement and licence agreement with Pfizer Inc. in relation to MSD’s pneu...
Pearce IP BioBlast®: w/e 01 October 2021

By Naomi Pearce | Oct 05, 2021

Read more

27 Sep 21 | Hikma Pharmaceuticals announced that it will acquire Custopharm for an initial cash consideration of USD $375 million with a further USD $50 million in contingent consid...